NR3C2 and diabetic kidney disease: Several studies have shown that the addition of aldosterone receptor blockade to ACEI or ARB blockade can lead to further reduction in albuminuria including in DKD [46–48], however long-term data on the efficacy of mineralocorticoid receptor antagonists on hard endpoints, for example the development of ESKD or patient survival, are still lacking.